MDmune-SensoriCure Sign MOU for Hearing Loss Treatment Development

From the left, Choi Byung-yoon, CTO of Sensory Cure; Kim Bong-jik, CEO; Bae Shin-gyu, CEO of MDmune; Kim Ho-kyung, Director.

[Asia Economy Reporter Kim Young-won] MDmune announced on the 13th that it has signed a joint research and development agreement for hearing loss treatment using cell-derived vesicles with SensoriCure, a company specializing in hearing loss diagnostic devices and therapeutics.

Through this joint research, the two companies plan to verify the efficacy of autoinflammatory hearing loss treatments using cell-derived vesicles (CDV) in animal models and mutually cooperate in discovering related intellectual property, securing rights, and commercializing the technology.

SensoriCure was founded by Professor Kim Bong-jik of the Department of Otorhinolaryngology at Sejong Chungnam National University Hospital and Professor Choi Byung-yoon of the Department of Otorhinolaryngology at Bundang Seoul National University Hospital. SensoriCure has established the world's first gene-based clinical guidelines for diagnosing and treating hearing loss in autoinflammatory diseases by analyzing patients and families with autoinflammatory diseases, including hearing loss patterns, drug treatment effects, and prognostic factors.

MDmune holds foundational patented technology for producing CDV by extruding human cells. CDV has higher productivity compared to exosomes and can utilize various source cells. MDmune is developing a next-generation drug delivery system bio-drone platform that loads various drugs onto CDV and delivers them to specific lesion tissues.

MDmune CEO Bae Shin-gyu said, "We are pleased to conduct joint research with SensoriCure, a specialized company in the field of hearing loss treatment, through this agreement," adding, "We also plan to develop gene therapies using hearing loss genetic information."

This content was produced with the assistance of AI translation services.